Brief: Immixbio Initiates GMP Manufacturing Of Drug for Inflammatory Bowel Disease
22/02/2022 13:28
Feb 22 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIXBIO INITIATES GMP MANUFACTURING OF IMX-120, A
BIOLOGIC FOR
INFLAMMATORY BOWEL DISEASE
* IMMIX BIOPHARMA INC - ANTICIPATES FILING AN IND FOR
IMX-120 IN
2023
Source text for Eikon: ID:nGNX5VMndg
Further company coverage: IMMX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary